Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, reported its financial results for the second quarter of 2025. The company recorded a net loss of approximately $2.5 million for the three months ended June 30, 2025, compared to a net loss of about $1.1 million for the same period in 2024. Research and development expenses increased to approximately $1.1 million from $0.5 million, driven primarily by clinical and pre-clinical study expenses. General and administrative expenses rose to $1.1 million from $0.7 million, attributed mainly to higher salaries and benefit expenses. Financial income, net was approximately $0.2 million, up from $0.1 million. As of June 30, 2025, cash and cash equivalents, short-term deposits, restricted cash, and marketable debt securities totaled approximately $20.7 million, compared to $15.4 million as of December 31, 2024. In August 2025, Galmed modified its participation in a previously announced exclusive license agreement with Entomus s.r.o. for a Self-Emulsifying Drug Delivery System (SEDDS) formulation, opting not to lead the project. Instead, a new UK-based company has been established for its development and commercialization, with Galmed planning to invest up to $2 million for up to 20% of its share capital, pending definitive documentation and board approval.